Pharvaris (NASDAQ:PHVS - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 390,900 shares, an increase of 25.7% from the January 31st total of 311,100 shares. Based on an average trading volume of 64,900 shares, the short-interest ratio is presently 6.0 days. Currently, 2.3% of the shares of the stock are sold short.
Analyst Ratings Changes
Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.
Read Our Latest Analysis on Pharvaris
Pharvaris Price Performance
NASDAQ PHVS traded down $0.44 during trading hours on Friday, hitting $15.01. 91,538 shares of the company's stock traded hands, compared to its average volume of 71,720. Pharvaris has a 52-week low of $14.14 and a 52-week high of $26.99. The company has a market capitalization of $784.87 million, a PE ratio of -5.36 and a beta of -3.02. The firm's 50-day moving average is $17.40 and its 200-day moving average is $19.20.
Institutional Trading of Pharvaris
Large investors have recently bought and sold shares of the business. Patient Square Capital LP purchased a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $4,488,000. Soleus Capital Management L.P. grew its stake in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares during the period. FMR LLC grew its stake in shares of Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after buying an additional 189,714 shares during the period. Octagon Capital Advisors LP grew its stake in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after buying an additional 157,530 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock valued at $8,510,000 after buying an additional 118,408 shares during the period.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
